Evidence map›Paper›PMID 35942259›Full record

ArticleFrontiers in public health2022

Impact of COVID-19 on tuberculosis detection and treatment in Baja California, México.

Raquel Muñiz-Salazar, Tina Le, Jazmine Cuevas-Mota, Jesús Eduardo González-Fagoaga, Rogelio Zapata-Garibay, Paola Saritzia Ruiz-Tamayo, Javier Robles-Flores, Richard S Garfein

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Medicinal Plants as Therapeutic Alternatives to CombatAntibiotics (Basel, Switzerland) · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Raquel Muñiz-SalazarEscuela de Ciencias de la Salud, Universidad Autónoma de Baja California, Ensenada, Mexico.
Tina LeHerbert Wertheim School of Public Health, University of California, San Diego, San Diego, CA, United States.
Jazmine Cuevas-MotaHerbert Wertheim School of Public Health, University of California, San Diego, San Diego, CA, United States.
Jesús Eduardo González-FagoagaHealthy Border Program, US-Mexico Border Heath Commission, Tijuana, Mexico.
Rogelio Zapata-GaribayHealthy Border Program, US-Mexico Border Heath Commission, Tijuana, Mexico.
Paola Saritzia Ruiz-TamayoEscuela de Ciencias de la Salud, Universidad Autónoma de Baja California, Ensenada, Mexico.
Javier Robles-FloresEscuela de Ciencias de la Salud, Universidad Autónoma de Baja California, Ensenada, Mexico.
Richard S GarfeinHerbert Wertheim School of Public Health, University of California, San Diego, San Diego, CA, United States.
Universidad Autónoma de Baja California · MXUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2020, Mexico reported the lowest tuberculosis (TB) incidence on record, and it is unclear to what extent COVID-19 has impacted TB surveillance, diagnosis, and treatment. It is important to understand COVID-19's impact in Baja California (BC), which has the highest TB burden in Mexico. With the increasing number of migrants and asylum seekers arriving in BC, limited resources and crowded living conditions increase the risk of TB transmission. The purpose of this study was to assess the impact of COVID-19 on TB diagnosis and treatment in BC. We were also interested in health disparities experienced by migrants in BC. We conducted a mixed methods analysis using quantitative surveillance data obtained from the Mexico National TB Program (NTP) and qualitative data collected through in-depth interviews and focus group discussions with TB program directors and personnel in BC's four provincial health jurisdictions. Compared to the year prior, surveillance data from March 2020 - February 2021 revealed that TB incidence in BC declined by 30.9% and favorable TB outcomes (TB cure or treatment completion) declined by 49.8%. Elucidating differences by migrant status was complicated by the lack of standardized collection of migrant status by the NTP. Qualitative analysis revealed that TB diagnostic and treatment supplies and services became limited and disproportionately accessible across jurisdictions since the pandemic began; however, favorable adaptations were also reported, such as increased telemedicine use and streamlined care referral processes. Participants shared that migrant status is susceptible to misclassification and that TB care is difficult due to the transitory nature of migrants. This study did not identify major differences in TB service delivery or access between migrants and non-migrants in BC; however, migrant status was frequently missing. COVID-19 has overwhelmed health systems worldwide, disrupting timely TB diagnostic and treatment services, and potentially caused underdiagnosis of TB in BC. TB programs in BC should quickly restore essential services that were disrupted by COVID-19 while identifying and preserving beneficial program adaptations, such as telemedicine and streamlined care referral processes. Improved methods for documenting migrant status of TB cases are also needed.

Indexed as

COVID-19RefugeesTransients and MigrantsTuberculosisHumansMexicoincidencemigrationMycobacterium tuberculosisqualitative analysisSARS-CoV-2

Identifiers

PMID35942259
PMCPMC9356343
OpenAlexW4286685297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.